Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CHF 5993 (BDP/FF/GB) pMDI in Healthy Volunteers
NCT05898984Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of beclomethasone dipropionate, formoterol and glycopyrronium bromide in asthma (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Area under the concentration-time curve from zero to last quantifiable time point and Maximum plasma concentration. Started Apr 2023; status: completed.
02
Drugs
beclomethasone dipropionateformoterolglycopyrronium bromide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05898984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898984.